Methods of treating cerebral amyloid angiopathy

• US 9,757,448 B2
• Filed: 02/24/2011
• Issued: 09/12/2017
• Est. Priority Date: 02/26/2010
• Status: Active Grant

• Current Assignee: Brigham and Women's Hospital Incorporated, Ramot at Tel Aviv University Limited (Tel Aviv University)
• Original Assignee: Brigham and Women's Hospital Incorporated, Ramot at Tel Aviv University Limited (Tel Aviv University)
• Inventors: Weiner, Howard, Frenkel, Dan, Lifshitz, Veronica
• Primary Examiner(s): Hartley, Michael
• Assistant Examiner(s): Cabral, Robert
• Application Number:
  US13/579,817
• Publication Number:
  US 20130183245A1
• Time in Patent Office: 2,392 Days
• CPC Class Codes: A61K 31/739 Lipopolysaccharides
• CPC Class Codes: A61K 38/164 from bacteria
• CPC Class Codes: A61K 39/39 characterised by the immunostimulating additives, e.g. chemical adjuvants
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

Methods for treating and reducing risk of cerebral amyloid angiopathy (CAA) using nasal vaccination with a proteosome adjuvant.

Claims

1. A method of treating Cerebral Amyloid Angiopathy (CAA) in a subject, the method comprising:

identifying a subject who has been diagnosed with CAA but who has not been diagnosed with Alzheimer'"'"'s Disease;

selecting the subject on the basis that they have CAA; and

nasally administering a therapeutically effective amount of a proteosome-based adjuvant to the identified subject.

2. The method of claim 1, further comprising diagnosing the subject with CAA.

3. The method of claim 2, wherein the diagnosis of CAA is made according to the Boston Cerebral Amyloid Angiopathy Group guidelines.

4. The method of claim 2, wherein the diagnosis is made based on the presence of a single lobar, cortical, or corticosubcortical hemorrhage without another cause, multiple hemorrhages with a possible but not a definite cause, or a hemorrhage in an atypical location.

5. The method of claim 1, further comprising administering one or more clinical tests to evaluate the effectiveness of the treatment.

6. The method of claim 5, wherein the clinical tests include one or more imaging studies.

7. The method of claim 5, wherein the clinical tests include a cognitive evaluation.

8. The method of claim 1, further comprising administering one or more treatments for CAA.

9. The method of claim 8, wherein the one or more treatments include surgical hematoma evacuation, or administration of a pharmaceutical.

11. The method of claim 9, wherein the pharmaceutical is a corticosteroid or cyclophosphamide.

10. A method of decreasing risk of recurrence of intracranial hemorrhage (ICH) in a subject who has had at least one diagnosed ICH and who has not been diagnosed with Alzheimer'"'"'s Disease, the method comprising:

identifying a subject who has had at least one diagnosed ICH, and nasally administering a therapeutically effective amount of a proteosome-based adjuvant to the identified subject.